AVIEW Aorta Metrics
Coreline Soft Co., Ltd. · Decision date Oct 16, 2026
What did the FDA decide?
The FDA recorded a substantially equivalent (SESE) decision for AVIEW Aorta Metrics, submitted by Coreline Soft Co., Ltd. of Seoul, KR, under 510(k) number K260391. The decision date is 2026-10-16; the application was received 02/06/2026. The device falls under regulation 892.1750, classification product code JAK, in the Radiology specialty and review panel, as a Traditional 510(k) not reviewed by a third party. SESE denotes clearance rather than PMA approval.
The public record identifies the device classification name as System, X-Ray, Tomography, Computed, and lists no combination product and no authorized Predetermined Change Control Plan. The source does not include a summary statement or describe the specific components, intended use, or any changed item, so the technical scope of this clearance remains unknown from the provided material. No clinical, efficacy, or patient-selection conclusions are drawn here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Oct 16, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260391
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Coreline Soft Co., Ltd.
- Product code
- JAK
- Decision code
- SESE
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, X-Ray, Tomography, Computed.
- Applicant
- Coreline Soft Co., Ltd.
- Product code
- JAK
- FDA device class
- 2
FDA decision timeline
K260391 received
Application receipt date recorded by FDA.
K260391 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code JAK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CAS-One IRK261225 | Cascination AG | 510(k) clearance | Sep 29, 2026 | FDA |
| Samsung HME America, Inc., dba NeuroLogica Corp. | 510(k) clearance | Sep 22, 2026 | FDA | |
SCENARIA View Phase 6.0K261229 | Fujifilm Corporation | 510(k) clearance | Sep 18, 2026 | FDA |
FCT iStream Phase 2K253836 | Fujifilm Corporation | 510(k) clearance | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Coreline Soft Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Seoul
Sources and methodology
- Original FDA record: K260391
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


